Figure 1. The role of GLP‐1 RAs in achieving weight loss and improving cardiovascular outcomes in people with overweight and obesity. ¹ , ² , ⁴ , ¹⁶ , ⁴⁹ , ⁵³ , ⁵⁴ , ⁵⁹ , ⁶² , ⁶³ , ⁶⁴ , ⁶⁸ , ⁷⁰ , ⁷¹ , ⁷² , ⁷³ , ⁷⁴ , ⁷⁶ , ⁷⁷ , ⁷⁸ , ⁸⁹ , ⁹⁹ , ¹⁰⁰ , ¹⁰⁵ , ¹⁰⁶ , ¹⁰⁷ , ¹⁰⁸ , ¹⁰⁹ , ¹¹⁰ .

BP indicates blood pressure; BMI, body mass index; CV, cardiovascular; CVD, cardiovascular disease; FDA, Food and Drug Administration; GI, gastrointestinal; GLP‐1 RA, glucagon‐like peptide‐1 receptor agonist; HCP, health care professional; MACE, major adverse cardiovascular event; s.c., subcutaneous; and T2D, type 2 diabetes.